Advertisement

Topics

Veracyte, Inc. Company Profile

17:07 EDT 24th September 2017 | BioPortfolio

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).


News Articles [33 Associated News Articles listed on BioPortfolio]

Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results ...

Veracyte, Inc.Media:Tracy Morris, 650-380-4413tracy.morris@veracyte.comorInvestors:Jackie Cossmon, 650-243-6371jackie@veracyte.com Read more...

Veracyte to Present at the Cantor Fitzgerald Global Healthcare Conference

Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Cantor Fitzgerald Global Healthcare Confere...

Veracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference

Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the Morgan Stanley 15th Annual Global Healthcar...

Veracyte to Present at William Blair 2017 Growth Stock Conference

SOUTH SAN FRANCISCO, Calif., June 1, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) today announced that Bonnie H. Anderson, chairman and chief executive officer, will present at the William ...

Veracyte to Host Conference Call and Webcast to Discuss Second Quarter 2017 Financial Results on Monday, July 31, 2017

Veracyte, Inc. (NASDAQ: VCYT) announced today that it will report its second quarter 2017 financial results after the close of market on Monday, July 31, 2017. Following th...

Veracyte Named a San Francisco Bay Area "Top Workplace" For Fourth Consecutive Year

SOUTH SAN FRANCISCO, Calif., June 26, 2017 /PRNewswire/ -- Veracyte, Inc. (NASDAQ: VCYT) announced today that it has been awarded a 2017 Top Workplaces honor by the Bay Area News Group. This mark...

Veracyte, Inc. 2017 Q2 - Results - Earnings Call Slides

Anthem to cover Veracyte's Afirma test for detecting thyroid cancer

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Veracyte, Inc.

Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable...

More Information about "Veracyte, Inc." on BioPortfolio

We have published hundreds of Veracyte, Inc. news stories on BioPortfolio along with dozens of Veracyte, Inc. Clinical Trials and PubMed Articles about Veracyte, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Veracyte, Inc. Companies in our database. You can also find out about relevant Veracyte, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record